Author:
Facchinetti Francesco,Gnetti Letizia,Balestra Valeria,Silva Mario,Silini Enrico Maria,Ventura Luigi,Majori Maria,Bordi Paola,Tiseo Marcello
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference10 articles.
1. Solomon BJ, Kim DW, Wu YL, et al. (2018) Final overall survival analysis from a study comparing first-line crizotinib with chemotherapy: results from PROFILE 1014. J Clin Oncol [Epub ahead of print]
2. Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M (2018) Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer 19(2):e151–e161
3. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ (2017) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18(12):1590–1599
4. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR (2017) Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 35(22):2490–2498
5. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, le L, McTigue M, Getz G, Johnson TW, Engelman JA (2016) Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374(1):54–61
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献